November 27, 2014 11:16 AM ET

Pharmaceuticals

Company Overview of Sagent Pharmaceuticals, Inc.

Company Overview

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronch...

1901 North Roselle Road

Suite 700

Schaumburg, IL 60195

United States

Founded in 2006

269 Employees

Phone:

847-908-1600

Fax:

847-908-1601

Key Executives for Sagent Pharmaceuticals, Inc.

Founder
Age: 65
Total Annual Compensation: $615.2K
President
Age: 55
Total Annual Compensation: $308.7K
Chief Financial Officer and Executive Vice President
Age: 50
Total Annual Compensation: $330.8K
Chief Legal Officer
Age: 50
Total Annual Compensation: $312.7K
Executive Vice President of National Accounts & Corporate Development
Age: 71
Total Annual Compensation: $287.4K
Compensation as of Fiscal Year 2013.

Sagent Pharmaceuticals, Inc. Key Developments

SGNT Seeks Acquisitions

Sagent Pharmaceuticals, Inc. (NasdaqGS:SGNT) is seeking acquisitions. SGNT has filed a shelf registration in the amount of $373 million. SGNT intend to use the net proceeds from any sale of securities we offer under this prospectus for general corporate purposes, which may include working capital, capital expenditures, acquisitions and other strategic initiatives and repayment of indebtedness.

Sagent Pharmaceuticals, Inc. Announces Un-Audited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Narrows Net Income Guidance for Fiscal Year 2014

Sagent Pharmaceuticals, Inc. announced un-audited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenue of $65.4 million, an increase of $4.5 million, or 7%, compared to $60.8 million in the third quarter of 2013. The increase was driven by $12.8 million in revenue from the launch of 29 new codes or presentations of 11 new products since September 30, 2013, partially offset by declines in the base business primarily related to price. The company reported income from operations of $4.0 million compared to $3.1 million, income before income taxes of $3.3 million compared to $2.8 million, net income of $1.9 million or $0.06 per diluted share compared to $2.8 million or $0.10 per diluted share and adjusted EBITDA of $7.2 million compared to $6.2 million for the last year. For the nine months, the company reported revenue of $205.4 million compared to $180.6 million, income from operations of $14.0 million compared to $26.4 million, income before income taxes of $12.9 million compared to $26.0 million, net income of $10.1 million or $0.31 per diluted share compared to $26.0 million or $0.90 per diluted share and adjusted EBITDA of $24.0 million compared to $33.6 million for the last year. Net revenue for the year 2014 to be in the range of $275 - $285 million driven by approximately ten product launches and the addition of Omega; Adjusted gross profit as a percentage of net revenue in the range of 30% to 33%. As a result, the company has narrowed its anticipated range for reported net income for fiscal 2014 to between $5 million and $10 million, before the impact of purchase accounting and other non-recurring costs.

Sagent Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 04, 2014

Sagent Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 9:00 AM, US Eastern Standard Time on Nov 04, 2014

Similar Private Companies By Industry

Company Name Region
Purdue Pharma Technologies Inc. United States
BPI Sports Holdings, LLC United States
Daiichi Sankyo, Inc. United States
Arbor Pharmaceuticals, LLC United States
Suncoast Clinical Research Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 1, 2014
Omega Laboratories Limited
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sagent Pharmaceuticals, Inc., please visit www.sagentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.